Nisha Durand - Search Results

Year	Number of Results
2013	1
2015	2
2016	3
2017	3
2018	3
2019	1
2020	2
2021	1
2022	3
2023	3
2024	0

1

Targeting reactive oxygen species in development and progression of pancreatic cancer.

Durand N, Storz P. Durand N, et al. Expert Rev Anticancer Ther. 2017 Jan;17(1):19-31. doi: 10.1080/14737140.2017.1261017. Epub 2016 Nov 23. Expert Rev Anticancer Ther. 2017. PMID: 27841037 Free PMC article. Review.

2

Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure.

Durand N, Mallea J, Zubair AC. Durand N, et al. NPJ Regen Med. 2020 Oct 26;5(1):17. doi: 10.1038/s41536-020-00105-z. NPJ Regen Med. 2020. PMID: 33580031 Free PMC article. Review.

3

Particulates are everywhere, but are they harmful in cell and gene therapies?

Molina SA, Davies SJ, Sethi D, Oh S, Durand N, Scott M, Davies LC, Wormuth K, Clarke D. Molina SA, et al. Among authors: durand n. Cytotherapy. 2022 Dec;24(12):1195-1200. doi: 10.1016/j.jcyt.2022.07.014. Epub 2022 Sep 27. Cytotherapy. 2022. PMID: 36175323 No abstract available.

4

Protein Kinase D Enzymes as Regulators of EMT and Cancer Cell Invasion.

Durand N, Borges S, Storz P. Durand N, et al. J Clin Med. 2016 Feb 3;5(2):20. doi: 10.3390/jcm5020020. J Clin Med. 2016. PMID: 26848698 Free PMC article. Review.

5

Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer.

Durand N, Borges S, Storz P. Durand N, et al. Cell Mol Life Sci. 2015 Nov;72(22):4369-82. doi: 10.1007/s00018-015-2011-2. Epub 2015 Aug 8. Cell Mol Life Sci. 2015. PMID: 26253275 Free PMC article. Review.

6

Autologous versus allogeneic mesenchymal stem cell therapy: The pros and cons.

Durand N, Zubair AC. Durand N, et al. Surgery. 2022 May;171(5):1440-1442. doi: 10.1016/j.surg.2021.10.057. Epub 2021 Dec 1. Surgery. 2022. PMID: 34863523 No abstract available.

7

Modifiers of mesenchymal stem cell quantity and quality.

Russell AL, Lefavor R, Durand N, Glover L, Zubair AC. Russell AL, et al. Among authors: durand n. Transfusion. 2018 Jun;58(6):1434-1440. doi: 10.1111/trf.14597. Epub 2018 Mar 26. Transfusion. 2018. PMID: 29582436

8

Mesenchymal Stem Cell Therapy in Acute Intracerebral Hemorrhage: A Dose-Escalation Safety and Tolerability Trial.

Durand NC, Kim HG, Patel VN, Turnbull MT, Siegel JL, Hodge DO, Tawk RG, Meschia JF, Freeman WD, Zubair AC. Durand NC, et al. Neurocrit Care. 2023 Dec 19. doi: 10.1007/s12028-023-01897-w. Online ahead of print. Neurocrit Care. 2023. PMID: 38114796

9

Feasibility and Safety of Low-Dose Mesenchymal Stem Cell Infusion in Lung Transplant Recipients.

Erasmus DB, Durand N, Alvarez FA, Narula T, Hodge DO, Zubair AC. Erasmus DB, et al. Among authors: durand n. Stem Cells Transl Med. 2022 Sep 21;11(9):891-899. doi: 10.1093/stcltm/szac051. Stem Cells Transl Med. 2022. PMID: 35881142 Free PMC article.

10

Early Stage Professionals Committee proceedings from the International Society for Cell & Gene Therapy 2022 Annual Meeting.

Lamb M, Wiest E, Filiano A, Russell A, Yarani R, Sutrave G, Durand N, Burga RA. Lamb M, et al. Among authors: durand n. Cytotherapy. 2023 Jun;25(6):590-597. doi: 10.1016/j.jcyt.2023.01.006. Epub 2023 Mar 10. Cytotherapy. 2023. PMID: 36906481

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

19 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year